An investor's guide to the sector and its regulations.
Minter Ellison's commercial health practice operates on a national and international basis to assist our clients in each sector of the health industry to achieve their commercial objectives. With our in-depth knowledge of the industry and its regulatory environment we tailor our services to the unique requirements of each client and matter.
Our expertise extends to mergers and acquisitions, investment, infrastructure, commercial contracts and associated contract management, outsourcing and procurement, intellectual property and information technology for public and private health service providers, the Commonwealth and State Departments of Health, private acute and day facilities, pharmaceutical companies, device manufactures and suppliers, health insurers, radiology and pathology providers.
On 31 December 2012, the China International Economic and Trade Arbitration Commission (CIETAC), a foreign-related arbitration commission set up by the China Council for the Promotion of International Trade (also known as the China Chamber of International Commerce) (CCPIT), released its Announcement on Issues Concerning CIETAC Shanghai Sub-Commission and CIETAC South China Sub-Commission" (the Latest Announcement). This is the latest development in a dispute, which has been on foot since April 2012, between CIETAC, the Shanghai Sub-Commission of CIETAC (CIETAC Shanghai), and the Shenzhen Court of International Arbitration (SCIA) (the CIETAC Dispute). SCIA was known as the South China Sub-Commission of CIETAC before 22 October 2012.
On Tuesday, 29 November 2011, as part of its Mid-Year Economic and Fiscal Outlook 2011-12, the Federal Government announced a package of changes intended to raise A$11.5 billion in new revenue and savings.